Galapagos NV
AEX:GLPG

Watchlist Manager
Galapagos NV Logo
Galapagos NV
AEX:GLPG
Watchlist
Price: 26.62 EUR -2.13% Market Closed
Market Cap: 1.8B EUR

Galapagos NV
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Galapagos NV
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Galapagos NV
AEX:GLPG
EPS (Diluted)
-€6
CAGR 3-Years
N/A
CAGR 5-Years
-3%
CAGR 10-Years
N/A
M
MDxHealth SA
NASDAQ:MDXH
EPS (Diluted)
-$1
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Oxurion NV
XBRU:OXUR
EPS (Diluted)
€0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Celyad Oncology SA
XBRU:CYAD
EPS (Diluted)
€0
CAGR 3-Years
48%
CAGR 5-Years
40%
CAGR 10-Years
N/A
European Medical Solutions
XBRU:ALEMS
EPS (Diluted)
€0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Galapagos NV
Glance View

Market Cap
1.8B EUR
Industry
Biotechnology

Founded in 1999, Galapagos NV emerged from the rich scientific collaboration between the Netherlands and Belgium, initially as a joint venture between the Dutch company Crucell and the Flemish biotech company Tibotec. In its early years, Galapagos carved a niche for itself by focusing on the discovery of novel targets leading to the development of human proteins for medicines. Through its proprietary technological platforms, Galapagos identifies and validates these targets, setting the stage for developing small molecules that inhibit these specific proteins. This unique approach positions the company at the forefront of innovative drug discovery, primarily targeting inflammatory diseases, fibrosis, and other conditions where there is a significant unmet medical need. Revenue for Galapagos is generated through several streams, most notably from strategic partnership deals and potential milestone payments in the biotech sector. The heart of its business model lies in deep collaborations with major pharmaceutical companies like Gilead Sciences, which bolster its financial stability and provide mutual benefits in drug development ventures. Additionally, Galapagos advances its proprietary drug candidates in clinical trials, aiming to bring them to market and secure approval from regulatory bodies. By successfully moving these candidates through clinical development phases, it stands to secure substantial future revenue from both commercialization and licensing deals. With its innovative science-focused strategy, Galapagos continues to propel forward, endeavoring to transform scientific insights into tangible therapeutic advancements.

GLPG Intrinsic Value
11.43 EUR
Overvaluation 57%
Intrinsic Value
Price

See Also

What is Galapagos NV's EPS (Diluted)?
EPS (Diluted)
-6.6 EUR

Based on the financial report for Sep 30, 2025, Galapagos NV's EPS (Diluted) amounts to -6.6 EUR.

What is Galapagos NV's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-3%

Back to Top